Oxford Immunotec Announces Launch of the Accutix Brand

Oxford Immunotec Global (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the Accutix brand for its tick-borne disease offering.

As quoted in the press release:

“Incorporating the feedback of our customers was a key consideration in our selection of a new brand name,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “Tick-borne disease specialists value the accuracy of our tests and the history and credibility of our lab in helping them diagnose Lyme and other tick-borne diseases. The Accutix name embodies these qualities and will assist us in building a market leadership position in the tick-borne disease diagnostics market.”

The Accutix brand aligns Oxford Immunotec’s tick-borne disease offering, which includes over 20 testing options targeting eight tick-borne diseases, under a unified name. The Company will continue to develop new assays for both existing and emerging tick-borne diseases under the Accutix brand.

Click here to read the full press release.